Oct 24, 2025elinzanetant is approved under the brand name lynkuet tm in australia, canada, the united kingdom and switzerland. Oct 24, 2025bayer’s lynkuet (elinzanetant), the first and only neurokinin 1 and neurokinin 3 receptor antagonist, receives fda approval for moderate to severe hot flashes due to menopause. Oct 24, 2025following positive safety and efficacy data, the fda has approved elinzanetant to manage vasomotor symptoms in postmenopausal women.
Oct 31, 2025seattle, wa – october 24, 2025 – seattle clinical research center (scrc) is proud to recognize the recent fda approval of elinzanetant (brand name lynkuet), developed by bayer, for. Oct 24, 2025bayer’s new small molecule drug, lynkuet (elinzanetant), recently approved by the u.s. Oct 25, 2025fda approval was supported by data from the phase iii oasis clinical trial program.
Oct 24, 2025what is lynkuet® (elinzanetant)?
'/><text x='50%' y='52%' font-family='Arial,Helvetica,sans-serif' font-size='44' fill='white' text-anchor='middle' dominant-baseline='middle'>Virginia</text></svg>)
